The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer

Chaokun Wang, Shuzhen Deng, Jing Chen, Xiangyun Xu, Xiaochen Hu, Dejiu Kong, Gaofeng Liang, Xiang Yuan, Yuanpei Li, Xinshuai WangFrontiers in Oncology 2021 · DOI

Abstract

Pyrotinib (PYR) is a pan-HER kinase inhibitor that inhibits signaling via the RAS/RAF/MEK/MAPK and PI3K/AKT pathways. In this study, we aimed to investigate the antitumor efficacy of pyrotinib combined with adriamycin (ADM) and explore its mechanisms on HER2+ breast cancer. We investigated the effects of PYR and ADM on breast cancer in vitro and in vivo. MTT assay, Wound-healing, and transwell invasion assays were used to determine the effects of PYR, ADM or PYR combined with ADM on cell proliferation, migration, and invasion of SK-BR-3 and AU565 cells in vitro. Cell apoptosis and cycle were detected through flow cytometry. In vivo, xenograft models were established to test the effect of PYR, ADM, or the combined therapy on the nude mice. Western blotting was performed to assess the expression of Akt, p-Akt, p-65, p-p65, and FOXC1. The results indicated that PYR and ADM significantly inhibited the proliferation, migration, and invasion of SK-BR-3 and AU565 cells, and the inhibitory rate of the combination group was higher than each monotherapy group. PYR induced G1 phase cell-cycle arrest, while ADM induced G2 phase arrest, while the combination group induced G2 phase arrest. The combined treatment showed synergistic anticancer activities. Moreover, PYR significantly downregulated the expression of p-Akt, p-p65, and FOXC1. In clinical settings, PYR also exerts satisfactory efficacy against breast cancer. These findings suggest that the combination of PYR and ADM shows synergistic effects both in vitro and in vivo. PYR suppresses the proliferation, migration, and invasion of breast cancers through down-regulation of the Akt/p65/FOXC1 pathway.

Introduction

Human epidermal growth factor receptor 2 (HER2) overexpression is a hallmark of approximately 15–20% of breast cancer cases, typically correlating with aggressive tumor progression and a poor clinical outlook. While targeted agents like trastuzumab have significantly improved outcomes, the development of resistance remains a major hurdle. Pyrotinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), and Adriamycin (ADM), a standard chemotherapeutic, represent two different therapeutic modalities. This study explores whether their combination yields synergistic antitumor effects and investigates the underlying molecular mechanisms, specifically focusing on the Akt/p65/FOXC1 signaling axis.

Materials and Methods

The study utilized two HER2-positive breast cancer cell lines, SK-BR-3 and AU565. Cell viability was assessed using MTT assays, while migration and invasion were evaluated via wound-healing and transwell assays, respectively. Synergy was quantitatively determined using the Chou-Talalay method to calculate the Combination Index (CI), where a CI < 1.0 denotes synergism. Cell cycle distribution and apoptosis were analyzed using flow cytometry. For in vivo validation, SK-BR-3 cells were implanted into female nude mice to establish xenograft models, which were treated with PYR, ADM, or the combination. Protein expression levels of p-Akt, p-p65, and FOXC1 were measured by Western blotting to elucidate the mechanism of action.

Results

Synergistic Inhibition of Cell Proliferation

Both PYR and ADM demonstrated dose-dependent inhibition of cell viability in SK-BR-3 and AU565 cells. Crucially, the combination of the two drugs resulted in significantly higher inhibition rates than either drug alone.

Cell viability curves for SK-BR-3 cells treated with PYR, ADM, and their combinations.

CI analysis confirmed that the interaction was synergistic across a range of concentrations, with values consistently below 1.0, indicating that the drugs enhance each other's efficacy.

Combination Index (CI) plot for AU565 cells, where values below the dashed line (CI < 1) indicate synergy.

Cell Cycle Arrest and Apoptosis

The drugs exerted complementary effects on the cell cycle. PYR monotherapy induced arrest in the G1 phase, whereas ADM monotherapy led to G2 phase arrest. Interestingly, the combination therapy primarily induced G2 phase arrest, effectively preventing cancer cells from completing division.

Suppression of the Akt/p65/FOXC1 Pathway

Molecular analysis revealed that PYR treatment significantly reduced the phosphorylation of Akt and p65, leading to a subsequent decrease in the expression of FOXC1. FOXC1 is a known driver of metastasis and tumor progression. By downregulating this pathway, the PYR+ADM combination effectively inhibited the migratory and invasive capabilities of the breast cancer cells.

In Vivo Efficacy and Clinical Observation

In the xenograft mouse model, the combination therapy achieved the greatest reduction in tumor volume and weight without causing significant systemic toxicity, as evidenced by stable animal weights. Furthermore, a clinical case of a 52-year-old patient with HER2+ breast cancer showed a partial response to Pyrotinib-based treatment, with reductions in both the primary tumor and metastatic lymph nodes.

Discussion and Conclusion

This study provides robust evidence that combining Pyrotinib with Adriamycin produces a synergistic "1+1 > 2" effect against HER2-positive breast cancer. The synergy is mediated through complementary cell cycle arrest and the targeted downregulation of the Akt/p65/FOXC1 signaling pathway. These findings suggest that this combination could be a potent therapeutic strategy, potentially overcoming resistance to single-agent therapies. While the clinical case is encouraging, further large-scale clinical trials are necessary to validate these results in broader patient populations.

Summary updated

Abstract

Pyrotinib (PYR) is a pan-HER kinase inhibitor that inhibits signaling <i>via</i> the RAS/RAF/MEK/MAPK and PI3K/AKT pathways. In this study, we aimed to investigate the antitumor efficacy of pyrotinib combined with adriamycin (ADM) and explore its mechanisms on HER2<sup>+</sup> breast cancer. We investigated the effects of PYR and ADM on breast cancer <i>in vitro</i> and <i>in vivo</i>. MTT assay, Wound-healing, and transwell invasion assays were used to determine the effects of PYR, ADM or PYR combined with ADM on cell proliferation, migration, and invasion of SK-BR-3 and AU565 cells <i>in vitro</i>. Cell apoptosis and cycle were detected through flow cytometry. <i>In vivo</i>, xenograft models were established to test the effect of PYR, ADM, or the combined therapy on the nude mice. Western blotting was performed to assess the expression of Akt, p-Akt, p-65, p-p65, and FOXC1. The results indicated that PYR and ADM significantly inhibited the proliferation, migration, and invasion of SK-BR-3 and AU565 cells, and the inhibitory rate of the combination group was higher than each monotherapy group. PYR induced G1 phase cell-cycle arrest, while ADM induced G2 phase arrest, while the combination group induced G2 phase arrest. The combined treatment showed synergistic anticancer activities. Moreover, PYR significantly downregulated the expression of p-Akt, p-p65, and FOXC1. In clinical settings, PYR also exerts satisfactory efficacy against breast cancer. These findings suggest that the combination of PYR and ADM shows synergistic effects both <i>in vitro</i> and <i>in vivo</i>. PYR suppresses the proliferation, migration, and invasion of breast cancers through down-regulation of the Akt/p65/FOXC1 pathway.
BibTeX
@inproceedings{wang2021synergistic,
  author = {Chaokun Wang and Shuzhen Deng and Jing Chen and Xiangyun Xu and Xiaochen Hu and Dejiu Kong and Gaofeng Liang and Xiang Yuan and Yuanpei Li and Xinshuai Wang},
  title = {{The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer}},
  booktitle = {Frontiers in Oncology},
  year = {2021},
  doi = {10.3389/fonc.2021.616443},
}
Figure